Chardan Capital Has Weak Outlook for Femasys FY2024 Earnings

Femasys Inc. (NASDAQ:FEMY) – Equities research analysts at Chardan Capital dropped their FY2024 earnings per share estimates for shares of Femasys in a research note issued on Wednesday, November 13th. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings of ($0.84) per share for the year, down from their previous forecast of ($0.79). Chardan Capital has a “Buy” rating and a $8.00 price objective on the stock. The consensus estimate for Femasys’ current full-year earnings is ($0.84) per share. Chardan Capital also issued estimates for Femasys’ FY2025 earnings at ($0.49) EPS.

Femasys (NASDAQ:FEMY) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million during the quarter, compared to the consensus estimate of $0.40 million. Femasys had a negative return on equity of 141.49% and a negative net margin of 1,435.77%.

Separately, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Femasys in a research note on Tuesday, November 12th.

Femasys Price Performance

Shares of FEMY stock opened at $0.89 on Monday. The firm has a fifty day moving average of $1.15 and a two-hundred day moving average of $1.14. The firm has a market cap of $20.29 million, a P/E ratio of -1.09 and a beta of -2.83. Femasys has a 1-year low of $0.73 and a 1-year high of $2.40. The company has a debt-to-equity ratio of 0.86, a current ratio of 3.94 and a quick ratio of 3.26.

Institutional Investors Weigh In On Femasys

Several institutional investors and hedge funds have recently made changes to their positions in FEMY. CM Management LLC boosted its holdings in Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock worth $484,000 after purchasing an additional 25,000 shares during the period. Aljian Capital Management LLC bought a new position in shares of Femasys in the 3rd quarter worth about $27,000. Geode Capital Management LLC boosted its holdings in shares of Femasys by 9.2% in the 3rd quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after buying an additional 17,473 shares during the period. Finally, XTX Topco Ltd grew its position in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock valued at $36,000 after buying an additional 18,004 shares during the last quarter. 65.27% of the stock is owned by institutional investors and hedge funds.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.